Taken together, these results indicate that DOX delivered as a CD133 aptamer-DOX conjugate can effectively impair the self-renewal of liver cancer stem cells, while a further boost in the efficacy of DOX in eliminating liver cancer stem cells can be accomplished by the inhibition of autophagy. Here, PROM1 is linked to liver cancer.